Biostax Corp (BTAX)

[tjguy]

Quote from the news release"

Immune Therapeutics to Achieve Profitability by YEAR-END
“We are excited to be partnering with Omaera Pharmaceuticals for the initial sale and distribution of Lodonal throughout Kenya,” said Noreen Griffin, Chairman and CEO of Immune Therapeutics, Inc. “Omaera is an innovative organization with very strong regional ties and a management team and board with strong local connections. This first-to-market opportunity has the potential to be a game changer in the treatment of HIV/AIDS as it demonstrates the continued growth in confidence and acceptance of Lodonal throughout the pharmaceutical industry.

The revenues generated from our successful launch of Lodonal in Kenya should enable us to achieve profitability BY THE MIDDLE OF 2018 and significantly strengthens our position to expand across additional countries, such as Nigeria, which is expected to be announced by the fourth quarter of this year,” concluded Ms. Griffin.

OK, so what does this mean? Previous guidance was for profitability this year. Is she pushing it back now to 1H 2018 OR is she saying that the Kenya deal, - assuming they get no other deals - is enough to reach profitability by 1H 2018?

In other words, if we get a deal in Nigeria, could they still reach profitability yet this year?